Total Payments
$223,773
2024 Payments
$33,340
Companies
18
Transactions
244
Payment Breakdown by Category
Consulting$130,313 (58.2%)
Travel$43,319 (19.4%)
Other$24,205 (10.8%)
Food & Beverage$16,372 (7.3%)
Research$9,533 (4.3%)
Education$30.06 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $130,313 | 43 | 58.2% |
| Travel and Lodging | $43,319 | 61 | 19.4% |
| Honoraria | $19,700 | 8 | 8.8% |
| Food and Beverage | $16,372 | 105 | 7.3% |
| Unspecified | $9,533 | 17 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,505 | 4 | 2.0% |
| Education | $30.06 | 6 | 0.0% |
Payments by Type
General
$214,240
227 transactions
Research
$9,533
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $49,782 | 35 | $0 (2024) |
| Novo Nordisk Health Care AG | $34,408 | 12 | $0 (2018) |
| Novo Nordisk Inc | $27,235 | 62 | $0 (2024) |
| Eton Pharmaceuticals, Inc. | $25,855 | 3 | $0 (2024) |
| Ascendis Pharma Inc | $18,563 | 11 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $17,682 | 28 | $0 (2024) |
| Daiichi Sankyo Inc. | $16,397 | 28 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $8,277 | 15 | $0 (2019) |
| Hexal AG | $7,765 | 6 | $0 (2019) |
| Endo Pharmaceuticals Inc. | $6,955 | 12 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,340 | 31 | Neurocrine Biosciences, Inc. ($11,181) |
| 2023 | $33,548 | 35 | Ascendis Pharma Inc ($12,636) |
| 2022 | $12,586 | 32 | Neurocrine Biosciences, Inc. ($5,451) |
| 2021 | $8,901 | 5 | Eton Pharmaceuticals, Inc. ($6,491) |
| 2020 | $16,037 | 12 | PFIZER INC. ($8,521) |
| 2019 | $20,893 | 36 | Hexal AG ($7,765) |
| 2018 | $55,283 | 54 | Novo Nordisk Health Care AG ($18,759) |
| 2017 | $43,184 | 39 | Novo Nordisk Health Care AG ($15,649) |
All Payment Transactions
244 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Neurocrine Biosciences, Inc. | CRENESSITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Neuropsychiatry | ||||||
| 11/16/2024 | PFIZER INC. | NGENLA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: NGENLA CLINICAL PUBLICATION PROGRAM • Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 10/10/2024 | PFIZER INC. | NGENLA (Drug) | — | In-kind items and services | $620.00 | Research |
| Study: NGENLA CLINICAL PUBLICATION PROGRAM • Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $120.00 | General |
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $24.79 | General |
| 09/16/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $16.40 | General |
| 09/09/2024 | PFIZER INC. | NGENLA (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $215.46 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $68.94 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $28.00 | General |
| 09/07/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 09/06/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $139.98 | General |
| 09/06/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $118.94 | General |
| 09/01/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $673.95 | General |
| 06/24/2024 | PFIZER INC. | NGENLA (Drug) | Consulting Fee | Cash or cash equivalent | $1,480.00 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 05/31/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $28.46 | General |
| 05/22/2024 | Tolmar, Inc. | FENSOLVI (Drug) | Food and Beverage | Cash or cash equivalent | $114.47 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 05/20/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: SOMATROGON CLINICAL PUBLICATION PROGRAM | ||||||
| 05/03/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $74.07 | General |
| 04/03/2024 | Ascendis Pharma Inc | Skytrofa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $785.00 | General |
| Category: Endocrinology | ||||||
| 03/29/2024 | Tolmar, Inc. | FENSOLVI (Drug) | Honoraria | Cash or cash equivalent | $2,140.00 | General |
| Category: HORMONE REPLACEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SOMATROGON CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 6 |
| NGENLA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,500 | 3 |
| TOL2581A | TOLMAR, INC. | $1,500 | 3 |
| TOL2581A-CPP | TOLMAR, INC. | $1,050 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN PEDIATRIC SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine Biosciences, Inc. | $750.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $533.31 | 1 |
About Dr. Mitchell Geffner, MD
Dr. Mitchell Geffner, MD is a Pediatric Endocrinology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043302391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Geffner, MD has received a total of $223,773 in payments from pharmaceutical and medical device companies, with $33,340 received in 2024. These payments were reported across 244 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($130,313).
Ad
Practice Information
- Specialty Pediatric Endocrinology
- Location Los Angeles, CA
- Active Since 09/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0205X
- Entity Type Individual
- NPI Number 1043302391
Products in Payments
- Norditropin (Drug) $53,213
- GENOTROPIN (Drug) $25,664
- ALKINDI (Drug) $19,364
- SKYTROFA (Drug) $14,245
- Welchol (Drug) $14,000
- NGENLA (Drug) $8,943
- Alkindi (Drug) $6,491
- Norditropin (Biological) $5,721
- SUPPRELIN LA (Drug) $5,451
- ZOMACTON (Drug) $5,190
- Skytrofa (Drug) $4,318
- SOMAVERT (Drug) $4,115
- FENSOLVI (Drug) $3,441
- Lupron (Drug) $3,115
- ENDOMETRIN (Drug) $3,088
- CRENESSITY (Drug) $2,500
- SUPPRELIN (Drug) $1,504
- TOL2581A (Drug) $1,500
- Eligard 45mg and CPP (Drug) $1,050
- ELIGARD (Drug) $499.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Endocrinology Doctors in Los Angeles
Francine Kaufman, M.d, M.D
Pediatric Endocrinology — Payments: $178,659
Pediatric Endocrinology $178,659
Nancy Chang, Np, NP
Pediatric Endocrinology — Payments: $24,559
Pediatric Endocrinology $24,559
Roshanak Monzavi, Md, MD
Pediatric Endocrinology — Payments: $19,121
Pediatric Endocrinology $19,121
Dr. Alaina Vidmar, M.d, M.D
Pediatric Endocrinology — Payments: $17,889
Pediatric Endocrinology $17,889
Lynda Fisher, Md, MD
Pediatric Endocrinology — Payments: $13,941
Pediatric Endocrinology $13,941
Dr. David Geller, M.d, M.D
Pediatric Endocrinology — Payments: $6,985
Pediatric Endocrinology $6,985